## AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended): A method of treating a blood product which contains a pathogen to be inactivated, said method comprising

a) adding psoralen to the blood product;

b) irradiating the psoralen and the blood product under conditions effective for said psoralen to inactivate said pathogen, thereby forming a mixture comprising said blood product, inactivated pathogen, free psoralen, and low molecular weight psoralen photoproducts; and

c) contacting said mixture with a hypercrosslinked resin to remove at least substantially all of said free psoralen and said low molecular weight psoralen photoproducts, wherein said hypercrosslinked resin is not pre-wetted with a wetting agent prior to said act of contacting said mixture with said hypercrosslinked resin.

Claim 2 (original): The method of claim 1 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 3 (original): The method of claim 1 wherein said blood product comprises plasma.

Claim 4 (cancelled)

Claim 5 (original): The method of claim 1 wherein said hypercrosslinked resin comprises a polyaromatic resin that is capable of adsorbing said free psoralen and said low molecular weight psoralen photoproducts.



PAGE 9/18 * RCVD AT 10/25/2005 10:19:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/27 * DNIS:2738300 * CSID:650 813 5993 * DURATION (mm-ss):04-12

Claim 6 (original): The method of claim 5 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 7 (original): The method of claim 6 wherein said aminopsoralen comprises 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen.

Claim 8 (currently amended): A method of removing psoralen free in solution from a biological fluid comprising blood or a blood product, said free psoralen having been exposed to light having a wavelength and in an a amount of light sufficient to cause a pathogen to be inactivated by said psoralen, the method comprising contacting said biological fluid with a hypercrosslinked adsorbent resin that is capable of removing said free psoralen without prewetting with a wetting agent; and removing at least substantially all of said free psoralen from said biological fluid with said hypercrosslinked adsorbent resin.

Claim 9 (original): The method of claim 8 wherein said resin is selected from the group consisting of: a polyaromatic resin having a mean surface area of about 1100 $m^2$/gm, a mean pore diameter of about 46Å, and a mesh size of about 20-50μm; a polyaromatic resin having a mean surface area of about 725 $m^2$/gm, a mean pore diameter of about 40Å, and a mesh size of about 20-60μm; and a functionalized polyaromatic resin having a mean surface area of about 800 $m^2$/gm, a mean pore diameter of about 25Å, and a mesh size of about 20-50μm.

Claim 10 (original): The method of claim 8 wherein said biological fluid comprises a plasma blood product.

Claim 11 (original): The method of claim 8 wherein said biological fluid comprises a platelet-containing blood product.



PAGE 10/18 * RCVD AT 10/25/2005 10:19:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/27 * DNIS:2738300 * CSID:650 813 5993 * DURATION (mm-ss):04-12

Claim 12 (original): The method of claim 11 wherein said biological fluid further comprises a synthetic medium containing phosphate.

Claim 13 (original): The method of claim 8 wherein said resin is not pre-wetted prior to contacting said biological fluid with said resin.

Claim 14 (original): The method of claim 8 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 15 (original): The method of claim 14 wherein said aminopsoralen comprises 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen.

Claim 16 (original): The method of claim 8 wherein said hypercrosslinked resin comprises a hypercrosslinked polyaromatic resin.

Claim 17 (original): The method of claim 16 wherein said biological fluid is selected from the group consisting of plasma and platelets.

Claim 18 (original): The method of claim 16 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 19 (withdrawn): The method of claim 16 wherein said psoralen comprises a brominated psoralen.

Claim 20 (previously presented): The method of claim 16 wherein the biological fluid further comprises low molecular weight psoralen photo products, and wherein said resin additionally removes at least substantially all of said low molecular weight psoralen photo products.

Claim 21 (original): A biological fluid formed by the method of claim 1.



PAGE 11/18 * RCVD AT 10/25/2005 10:19:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/27 * DNIS:2738300 * CSID:650 813 5993 * DURATION (mm-ss):04-12

Claim 22 (original): A biological fluid formed by the method of claim 3.

Claim 23 (original): A biological fluid formed by the method of claim 8.

Claim 24 (original): A biological fluid formed by the method of claim 12.

Claim 25 (previously presented): The method of claim 1 wherein said blood product comprises platelets.



PAGE 12/18 * RCVD AT 10/25/2005 10:19:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/27 * DNIS:2738300 * CSID:650 813 5993 * DURATION (mm-ss):04-12